Marco Taglietti
CIK 1408870 · Chief Executive Officer · last filed 2026-06-12
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
SCYX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
909 THIRD AVENUE
NEW YORK, NY 10022
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| AQST | Director | — | $3.97 | — | $0 | 7 | 2026-06-12 |
| SCYX | Chief Executive Officer | 34,008 | $3.81 | $129.6K | $2.13M | 35 | 2022-04-28 |
| DCTH | Director | 6,001 | $14.51 | $87.1K | $106.8K | 6 | 2020-05-08 |
| NephroGenex, Inc. (NRX) Delisted | Director | — | — | — | $0 | 2 | 2015-05-04 |
| Forest Laboratories, LLC (FRX) Delisted | EVP-Drug Dev & Ch.Medical Off. | 100,486 | $12.00 | $1.21M | -$663.9K | 23 | 2013-12-10 |
Recent Filings · Page 2 of 8
74 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-12-23 | SCYX | Mixed | +40,000 | $250.0K | EDGAR |
| 2020-05-08 | DCTH | Conv (C) | +6,000 | $0 | EDGAR |
| 2020-02-04 | SCYX | Grant (A) | — | $0 | EDGAR |
| 2019-12-16 | SCYX | Buy (P) | +166,667 | $150.0K | EDGAR |
| 2019-08-22 | SCYX | Buy (P) | +10,000 | $11.1K | EDGAR |
| 2019-08-19 | SCYX | Buy (P) | +10,015 | $10.1K | EDGAR |
| 2019-07-26 | DCTH | Buy (P) | — | $0 | EDGAR |
| 2019-04-18 | SCYX | Buy (P) | +25,000 | $40.8K | EDGAR |
| 2019-02-19 | SCYX | Grant (A) | — | $0 | EDGAR |
| 2019-02-05 | DCTH | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.